BioNTech's Q4 2024 revenue surpassed estimates, totaling 1.19 billion euros. EPS reached 1.08 euros, vastly exceeding the expected 0.42 euros, showcasing strong earnings management. Revenue from ...
In the last three months, 4 analysts have published ratings on BioNTech (NASDAQ:BNTX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...
Pfizer and BioNTech have announced that they have submitted an Emergency Use Authorisation (EUA) to the US Food and Drug Administration (FDA) for their Omicron BA.4/BA.5-adapted bivalent COVID-19 ...
March 10, 2025 BioNTech guides for worse-than-expected 2025 revenue decline German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion ...
Alman biyoteknoloji şirketi BioNTech, 2024 yılı dördüncü çeyrek ve yıllık finansal verilerini paylaştı. 2023’te 930,3 milyon euro net kâr açıklayan şirket, geçen yıl 665,3 milyon euro net zarar etti.
Buldukları aşı ile BioNTech hisseleri büyük değer kazanırken, şimdi 100 Euro’lara kadar indi. Şirketin son 4 haftadaki kaybı yüzde 12 oldu. Bunun nedenlerinden biri olarak Amerikan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback